DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Niaspan (Niacin Extended-Release) - Published Studies

 
 



Niaspan Related Published Studies

Well-designed clinical trials related to Niaspan (Niacin Extended-Release)

Changes in lipoprotein particle number with ezetimibe/simvastatin coadministered with extended-release niacin in hyperlipidemic patients. [2013]

MRI-measured regression of carotid atherosclerosis induced by statins with and without niacin in a randomised controlled trial: the NIA plaque study. [2013]

Extended-release niacin acutely suppresses postprandial triglyceridemia. [2012]

Extended-release niacin/laropiprant lowers serum phosphorus concentrations in patients with type 2 diabetes. [2011.07]

Assessment of potential pharmacokinetic interactions of ezetimibe/simvastatin and extended-release niacin tablets in healthy subjects. [2011.05]

Safety, tolerance, and efficacy of extended-release niacin monotherapy for treating dyslipidemia risks in persons with chronic tetraplegia: a randomized multicenter controlled trial. [2011.03]

Combination of niacin extended-release and simvastatin results in a less atherogenic lipid profile than atorvastatin monotherapy. [2010.11.24]

Efficacy and tolerability of extended-release niacin/laropiprant in dyslipidemic patients with metabolic syndrome. [2010.11]

Long-term efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in hyperlipidaemic patients with diabetes or metabolic syndrome. [2010.11]

Optimal pharmacologic approach to patients with hypertriglyceridemia and low high-density lipoprotein-cholesterol: randomized comparison of fenofibrate 160 mg and niacin 1500 mg. [2010.11]

Effect of fenofibrate and niacin on intrahepatic triglyceride content, very low-density lipoprotein kinetics, and insulin action in obese subjects with nonalcoholic fatty liver disease. [2010.06]

Effect of niacin ER/lovastatin on claudication symptoms in patients with peripheral artery disease. [2010.06]

Efficacy and safety of extended-release niacin/laropiprant plus statin vs. doubling the dose of statin in patients with primary hypercholesterolaemia or mixed dyslipidaemia. [2010.05]

Short-term effects of extended-release niacin on endothelial function in HIV-infected patients on stable antiretroviral therapy. [2010.04.24]

Hypophosphatemic effect of niacin in patients without renal failure: a randomized trial. [2010.04]

Safety of extended-release niacin/laropiprant in patients with dyslipidemia. [2010.03]

Long-term safety and efficacy of triple combination ezetimibe/simvastatin plus extended-release niacin in patients with hyperlipidemia. [2010.02.15]

Endothelial-vasoprotective effects of high-density lipoprotein are impaired in patients with type 2 diabetes mellitus but are improved after extended-release niacin therapy. [2010.01.05]

Effects of extended release niacin/laropiprant, laropiprant, extended release niacin and placebo on platelet aggregation and bleeding time in healthy subjects. [2010]

Hypophosphatemic effect of niacin in patients without renal failure: a randomized trial. [2010]

Effect of niacin ER/lovastatin on claudication symptoms in patients with peripheral artery disease. [2010]

Laropiprant in combination with extended-release niacin does not alter urine 11-dehydrothromboxane B2, a marker of in vivo platelet function, in healthy, hypercholesterolemic, and diabetic subjects. [2009.12]

Extended-release niacin or ezetimibe and carotid intima-media thickness. [2009.11.26]

Extended-release niacin (nicotinic acid)/laropiprant. [2009.08.20]

Flushing profile of extended-release niacin/laropiprant versus gradually titrated niacin extended-release in patients with dyslipidemia with and without ischemic cardiovascular disease. [2009.07.01]

Effects of extended-release niacin on lipid profile and adipocyte biology in patients with impaired glucose tolerance. [2009.07]

Effects of oral niacin on endothelial dysfunction in patients with coronary artery disease: results of the randomized, double-blind, placebo-controlled INEF study. [2009.05]

Effects of aspirin when added to the prostaglandin D2 receptor antagonist laropiprant on niacin-induced flushing symptoms. [2009.04]

Blood pressure-lowering effects of extended-release niacin alone and extended-release niacin/laropiprant combination: a post hoc analysis of a 24-week, placebo-controlled trial in dyslipidemic patients. [2009.01]

A comparison of the pharmacokinetics of two different formulations of extended-release niacin. [2009.01]

Emtricitabine/tenofovir disoproxil fumarate: in combination with a protease inhibitor in HIV-1 infection. [2009]

Acetylsalicylic acid reduces niacin extended-release-induced flushing in patients with dyslipidemia. [2009]

Flushing ASsessment Tool (FAST): psychometric properties of a new measure assessing flushing symptoms and clinical impact of niacin therapy. [2009]

Extended-release niacin alters the metabolism of plasma apolipoprotein (Apo) A-I and ApoB-containing lipoproteins. [2008.09]

Postprandial triglyceride responses to aerobic exercise and extended-release niacin. [2008.07]

Comparison of the safety and efficacy of a combination tablet of niacin extended release and simvastatin vs simvastatin monotherapy in patients with increased non-HDL cholesterol (from the SEACOAST I study). [2008.05.15]

Lipid-altering efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in patients with type IIa or type IIb hyperlipidemia. [2008.04.22]

The comparative bioavailability of an extended-release niacin and lovastatin fixed dose combination tablet versus extended-release niacin tablet, lovastatin tablet and a combination of extended-release niacin tablet and lovastatin tablet. [2007.09]

Validation of a questionnaire to assess niacin-induced cutaneous flushing. [2007.07]

Suppression of niacin-induced vasodilation with an antagonist to prostaglandin D2 receptor subtype 1. [2007.06]

Comparative effects on lipid levels of combination therapy with a statin and extended-release niacin or ezetimibe versus a statin alone (the COMPELL study). [2007.06]

Aspirin reduces cutaneous flushing after administration of an optimized extended-release niacin formulation. [2007.02]

Relationship between glycemic status and progression of carotid intima-media thickness during treatment with combined statin and extended-release niacin in ARBITER 2. [2007]

Improved control of niacin-induced flushing using an optimized once-daily, extended-release niacin formulation. [2006.12]

Effects of extended-release niacin on lipoprotein particle size, distribution, and inflammatory markers in patients with coronary artery disease. [2006.09.15]

An open-label, crossover study of the pharmacokinetics of Insoluble Drug Delivery-MicroParticle fenofibrate in combination with atorvastatin, simvastatin, and extended-release niacin in healthy volunteers. [2006.01]

Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. [2004.12.07]

Rosuvastatin alone or with extended-release niacin: a new therapeutic option for patients with combined hyperlipidemia. [2004.09]

Efficacy of extended-release niacin with lovastatin for hypercholesterolemia: assessing all reasonable doses with innovative surface graph analysis. [2004.05.24]

Effects of extended-release niacin on lipoprotein subclass distribution. [2003.06.15]

Beneficial effects of rosuvastatin alone and in combination with extended-release niacin in patients with a combined hyperlipidemia and low high-density lipoprotein cholesterol levels. [2003.06.01]

Comparison of once-daily, niacin extended-release/lovastatin with standard doses of atorvastatin and simvastatin (the ADvicor Versus Other Cholesterol-Modulating Agents Trial Evaluation [ADVOCATE]). [2003.03.15]

A dose-ranging study of a new, once-daily, dual-component drug product containing niacin extended-release and lovastatin. [2003.03]

Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial. [2002.07.22]

Long-term safety and efficacy of a once-daily niacin/lovastatin formulation for patients with dyslipidemia. [2002.03.15]

Niacin, but not gemfibrozil, selectively increases LP-AI, a cardioprotective subfraction of HDL, in patients with low HDL cholesterol. [2001.11]

Multiple-dose efficacy and safety of an extended-release form of niacin in the management of hyperlipidemia. [2000.05.01]

Extended-release niacin vs gemfibrozil for the treatment of low levels of high-density lipoprotein cholesterol. Niaspan-Gemfibrozil Study Group. [2000.04.24]

Clinical trial experience with extended-release niacin (Niaspan): dose-escalation study. [1998.12.17]

Effectiveness of once-nightly dosing of extended-release niacin alone and in combination for hypercholesterolemia. [1998.09.15]

Equivalent efficacy of a time-release form of niacin (Niaspan) given once-a-night versus plain niacin in the management of hyperlipidemia. [1998.09]

Treatment Effect of Niaspan, a Controlled-release Niacin, in Patients With Hypercholesterolemia: A Placebo-controlled Trial. [1996.07]

Well-designed clinical trials possibly related to Niaspan (Niacin Extended-Release)

The Effect of Lipid Modification on Peripheral Artery Disease after Endovascular Intervention Trial (ELIMIT). [2013]

Efficacy and tolerability of a new extended-release formulation of nicotinic acid in Korean adults with mixed dyslipidemia: an 8-week, multicenter, prospective, randomized, double-blind, and placebo-controlled trial. [2011.10]

The ARBITER 6-HALTS Trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6-HDL and LDL Treatment Strategies in Atherosclerosis): final results and the impact of medication adherence, dose, and treatment duration. [2010.06.15]

Effects of high-dose modified-release nicotinic acid on atherosclerosis and vascular function: a randomized, placebo-controlled, magnetic resonance imaging study. [2009.11.03]

Differential effect of two nicotinic acid preparations on low-density lipoprotein subclass distribution in patients classified as low-density lipoprotein pattern A, B, or I. [2004.09.01]

Comparative efficacy and safety of pravastatin, nicotinic acid and the two combined in patients with hypercholesterolemia. [1994.02.15]

Other research related to Niaspan (Niacin Extended-Release)

Effect of niacin on high-density lipoprotein apolipoprotein A-I kinetics in statin-treated patients with type 2 diabetes mellitus. [2014]

Effect of extended-release niacin on serum lipids and on endothelial function in adults with sickle cell anemia and low high-density lipoprotein cholesterol levels. [2013]

Extended-release niacin therapy and risk of ischemic stroke in patients with cardiovascular disease: the Atherothrombosis Intervention in Metabolic Syndrome with low HDL/High Triglycerides: Impact on Global Health Outcome (AIM-HIGH) trial. [2013]

The effects of extended release niacin on lipoprotein sub-particle concentrations in HIV-infected patients. [2013]

Wax-matrix extended-release niacin vs inositol hexanicotinate: a comparison of wax-matrix, extended-release niacin to inositol hexanicotinate "no-flush" niacin in persons with mild to moderate dyslipidemia. [2013]

Niacin improves lipid profile but not endothelial function in patients with coronary artery disease on high dose statin therapy. [2013]

Effect of extended-release niacin on new-onset diabetes among hyperlipidemic patients treated with ezetimibe/simvastatin in a randomized controlled trial. [2012]

Niacin extended-release therapy in phase III clinical trials is associated with relatively low rates of drug discontinuation due to flushing and treatment-related adverse events: a pooled analysis. [2011.06.01]

The resurgence of niacin: from nicotinic acid to niaspan/laropiprant. [2011.06]

Important considerations for treatment with dietary supplement versus prescription niacin products. [2011.03]

Niacin results in reduced monocyte adhesion in patients with type 2 diabetes mellitus. [2011.03]

Pharmacokinetics and dose recommendations of Niaspan(R) in chronic kidney disease and dialysis patients. [2011.01]

The role of niacin in raising high-density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low-density lipoprotein cholesterol: baseline characteristics of study participants. The Atherothrombosis Intervention in Metabolic syndrome with low HDL/high triglycerides: impact on Global Health outcomes (AIM-HIGH) trial. [2011]

The role of niacin in raising high-density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low-density lipoprotein cholesterol Rationale and study design. The Atherothrombosis Intervention in Metabolic syndrome with low HDL/high triglycerides: Impact on Global Health outcomes (AIM-HIGH). [2011]

Safety, tolerance, and efficacy of extended-release niacin monotherapy for treating dyslipidemia risks in persons with chronic tetraplegia: a randomized multicenter controlled trial. [2011]

Lipid and transaminase concentrations after formulary conversion of Niaspan to Slo-Niacin. [2010.12.01]

Niaspan treatment induces neuroprotection after stroke. [2010.10]

Niacin treatment of stroke increases synaptic plasticity and axon growth in rats. [2010.09]

Combination treatment of experimental stroke with Niaspan and Simvastatin, reduces axonal damage and improves functional outcome. [2010.07.15]

Effect of fenofibrate and niacin on intrahepatic triglyceride content, very low-density lipoprotein kinetics, and insulin action in obese subjects with nonalcoholic fatty liver disease. [2010]

Combination of niacin extended-release and simvastatin results in a less atherogenic lipid profile than atorvastatin monotherapy. [2010]

Efficacy and tolerability of extended-release niacin/laropiprant in dyslipidemic patients with metabolic syndrome. [2010]

Long-term efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in hyperlipidaemic patients with diabetes or metabolic syndrome. [2010]

Optimal pharmacologic approach to patients with hypertriglyceridemia and low high-density lipoprotein-cholesterol: randomized comparison of fenofibrate 160 mg and niacin 1500 mg. [2010]

Efficacy and safety of extended-release niacin/laropiprant plus statin vs. doubling the dose of statin in patients with primary hypercholesterolaemia or mixed dyslipidaemia. [2010]

Short-term effects of extended-release niacin on endothelial function in HIV-infected patients on stable antiretroviral therapy. [2010]

Long-term safety and efficacy of triple combination ezetimibe/simvastatin plus extended-release niacin in patients with hyperlipidemia. [2010]

Combined use of extended-release niacin and atorvastatin: safety and effects on lipid modification. [2009.07.20]

Extended-release niacin decreases serum fetuin-A concentrations in individuals with metabolic syndrome. [2009.07]

Niaspan treatment increases tumor necrosis factor-alpha-converting enzyme and promotes arteriogenesis after stroke. [2009.05]

Does nicotinic acid (niacin) lower blood pressure? [2009.01]

Niacin: an old drug rejuvenated. [2009.01]

Flushing profile of extended-release niacin/laropiprant at initiation of therapy in asian lipid clinic patients. [2009]

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2014